Results 1 to 10 of about 43,621 (186)

Dose-Dependent Pharmacokinetics of Tofacitinib in Rats: Influence of Hepatic and Intestinal First-Pass Metabolism

Pharmaceutics, 2019
This study investigated the pharmacokinetics of tofacitinib in rats and the effects of first-pass metabolism on tofacitinib pharmacokinetics. Intravenous administration of 5, 10, 20, and 50 mg/kg tofacitinib showed that the dose-normalized area under the
So Hee Kim, Kim So Hee
exaly   +3 more sources

Tofacitinib for refractory uveitis and scleritis

American Journal of Ophthalmology Case Reports, 2019
Purpose: To report the successful use of tofacitinib in the treatment of refractory uveitis and scleritis. Observations: Two patients, one with scleritis and another with anterior and intermediate uveitis, presented with refractory disease after failure ...
Michael A Paley, Hümeyra Karaçal, Jonathan J Miner   +2 more
exaly   +3 more sources

Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study

RMD Open, 2023
Objective To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis.Methods Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying ...
Yuko Kaneko, Hideto Kameda, Yoshiya Tanaka, Satoshi Kubo, Koichi Amano, Shingo Nakayamada, Yusuke Miyazaki, Kiyoshi Matsui, Yoshino Inoue, Kunihiro Yamaoka, Takehisa Ogura   +10 more
doaj   +1 more source

Tofacitinib Suppresses Natural Killer Cells In Vitro and In Vivo: Implications for Amyotrophic Lateral Sclerosis

Frontiers in Immunology, 2022
Amyotrophic lateral sclerosis (ALS) is a fatal and incurable neurodegenerative disease with few therapeutic options. However, the immune system, including natural killer (NK) cells, is linked to ALS progression and may constitute a viable therapeutic ALS
Claudia Figueroa-Romero, Alina Monteagudo, Benjamin J. Murdock, Joshua P. Famie, Ian F. Webber-Davis, Caroline E. Piecuch, Samuel J. Teener, Crystal Pacut, Stephen A. Goutman, Eva L. Feldman   +9 more
doaj   +1 more source

Tofacitinib [PDF]

Hospital Pharmacy, 2013
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J, Demaris, Kendra, Levien, Terri L, Baker, Danial E   +3 more
openaire   +3 more sources

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis

BMC Gastroenterology, 2022
Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe the real-world treatment experience and corticosteroid utilisation of patients treated with tofacitinib in a US claims database.
Michael V. Chiorean, Jessica R. Allegretti, Puza P. Sharma, Benjamin Chastek, Leonardo Salese, Elizabeth J. Bell, Jesse Peterson-Brandt, Joseph C. Cappelleri, Xiang Guo, Nabeel Khan   +9 more
doaj   +1 more source

Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study

RMD Open, 2023
Objectives Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) psoriatic arthritis (PsA) and inadequate response to ≥1 conventional ...
Xiaofeng Zeng, Cunshan Wang, Yi Liu, Jian Xu, Ju Liu, Zhuoli Zhang, Wenfeng Tan, Shengyun Liu, Wei Lin, Weiguo Wan, Zhenyu Jiang, Zhiyi Zhang, Oluwaseyi Dina, Shixue Liu, XiaoMei Leng, Keith Kanik, Jiankang Hu, Jingyang Li, Levent M. Gunay, Cassandra Kinch   +19 more
doaj   +1 more source

Fracture in clinical studies of tofacitinib in rheumatoid arthritis

Therapeutic Advances in Musculoskeletal Disease, 2022
Background: Preclinical data suggest that tofacitinib would protect bone health in patients with rheumatoid arthritis (RA). Objective: To assess fracture risk in tofacitinib RA clinical trials. Design: Post hoc analysis.
Karen E. Hansen, Mahta Mortezavi, Edward Nagy, Cunshan Wang, Carol A. Connell, Zaher Radi, Heather J. Litman, Giovanni Adami, Maurizio Rossini   +8 more
doaj   +1 more source

Tofacitinib as a maintenance therapy in patients with ulcerative colitis stratified by OCTAVE Sustain baseline Mayo endoscopic subscore

BMC Gastroenterology, 2023
Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We evaluated tofacitinib efficacy and safety in the 52-week maintenance study, OCTAVE Sustain, by baseline Mayo endoscopic subscore (MES ...
Scott D. Lee, Jessica R. Allegretti, Flavio Steinwurz, Susan B. Connelly, Nervin Lawendy, Jerome Paulissen, Krisztina B. Gecse   +6 more
doaj   +1 more source

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

Rheumatology and Therapy, 2022
Introduction This post hoc analysis evaluated influenza adverse events (AEs) across rheumatoid arthritis (RA), ulcerative colitis (UC), and psoriatic arthritis (PsA) tofacitinib clinical programs. Methods Available data from phase 1, randomized phase 2/3/
Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen   +14 more
doaj   +1 more source